GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Gilead's perfect profitability sub-score of 20.0/20 derived from its FY 2025 10-K is the primary driver of the 70.6 composite, anchoring the score with best-in-class net and operating margin performance as reported.
- The growth sub-score of 15.0/20 and momentum sub-score of 15.0/20 both contribute meaningfully, indicating that EDGAR-sourced data shows positive year-over-year and sequential operational improvement rather than a stagnant or declining trajectory.
- The dividend sub-score of 13.8/20 adds incremental score support by reflecting an FCF-backed dividend with a multi-year DPS history, reinforcing Gilead's positioning as a research candidate within the dividend income goal profile.
Why Not Higher
- The theme sub-score of 0.0/20 is the single largest ceiling constraint on the model score; had Gilead registered even moderate macro theme exposure in its 10-K, the composite score could have risen materially toward or above 80.
- The financial health sub-score of 14.0/20 — rather than a higher tier — reflects balance sheet leverage that prevents the model from awarding full marks, and until the leverage ratio and interest coverage metrics improve in future filings, this sub-score is likely to remain a cap on the overall rating.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, focused primarily on the discovery, development, and commercialization of medicines in therapeutic areas including HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. Its flagship HIV franchise — anchored by products such as Biktarvy and Descovy — generates the bulk of its revenue, while its oncology portfolio (including cell therapy products Yescarta and Tecartus) and hepatitis C treatments round out a diversified drug pipeline. The company's FY 2025 10-K filing underpins all scoring data here. The model assigned Gilead a score of 70.6/100, reflecting a company with genuine operational strengths offset by identifiable structural limitations. Profitability (20.0/20) and growth (15.0/20) are standout sub-scores, indicating strong net and operating margins alongside meaningful revenue and earnings expansion as filed. Financial health (14.0/20) and momentum (15.0/20) are solid but not maximal, suggesting the balance sheet carries notable leverage — consistent with Gilead's history of large acquisitions — and that sequential quarterly improvement has been real but not uniformly accelerating. The dividend sub-score of 13.8/20 reflects credible free-cash-flow coverage of its dividend and a track record of dividend-per-share growth, but the FCF payout ratio or DPS growth CAGR may not be at the highest tier. The theme score of 0.0/20 is a meaningful drag, indicating the scoring model found no counted macro theme exposures in the filing data. The central research tradeoff for Gilead is between its durable, cash-generative HIV franchise and dividend income profile on one hand, and its leverage position, theme score absence, and dependence on a concentrated therapeutic area on the other. The best-fit goal profile per the model is dividend income (74.4), making Gilead most relevant as a research candidate for income-oriented researchers willing to accept medium-level risk.
Plain English
Gilead Sciences makes medicines for serious diseases like HIV, hepatitis, and certain cancers, and it's one of the biggest names in the HIV treatment market. A score of 70.6 out of 100 means the model sees it as a reasonably solid company with strong profits and a real dividend history, but also some concerns like a leveraged balance sheet and no macro theme exposure picked up by the model. The Medium risk rating reflects that Gilead isn't a high-flying speculative bet, but it does carry real risks from drug pipeline concentration and debt. Researchers focused on dividend income will find it most interesting, while those seeking high growth or thematic exposure may find it less compelling.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 20.0/20 — the maximum possible — signals that Gilead's net margin, operating margin, and return on assets as reported in its FY 2025 10-K are at the top tier of the scoring model, reflecting the cash-generation power of its established HIV franchise.
- The growth sub-score of 15.0/20 indicates measurable year-over-year revenue, net income, and EPS expansion as derived from EDGAR filings, suggesting Gilead's oncology cell therapy portfolio and HIV product evolution are contributing to compounding top- and bottom-line improvement.
- The dividend sub-score of 13.8/20 reflects a filing-supported track record of dividend-per-share growth and free-cash-flow coverage, making Gilead a credible research candidate for income-oriented goal profiles, as confirmed by its best-fit profile score of 74.4 in dividend income.
Bear Case
- The financial health sub-score of 14.0/20 — below the model's upper range — points to elevated leverage ratios and interest coverage that falls short of the strongest-rated peers, consistent with Gilead's history of debt-funded acquisitions including Kite Pharma and Immunomedics.
- The theme sub-score of 0.0/20 is a material drag on the overall score, indicating the scoring model identified no qualifying macro theme exposures in the FY 2025 10-K filing, which limits Gilead's appeal for researchers seeking thematic or secular tailwind exposure.
- The weakest goal-profile score is speculative opportunities at 69.2, reflecting that Gilead's established, mature franchise structure does not fit a high-conviction growth or disruption research narrative under the current filing data.
What Could Change the Picture
Bullish Triggers
- If a future annual 10-K filing shows meaningful debt reduction and improved interest coverage ratios that push the financial health sub-score toward 17–20, the composite model score could rise significantly and reduce the medium risk rating.
- If Gilead's cell therapy oncology or inflammatory disease pipeline generates filing-evidenced revenue acceleration that registers qualifying macro theme exposure in the scoring model, the addition of theme score points from 0.0 would be a direct upside catalyst to the composite.
Bearish Triggers
- A deterioration in the profitability sub-score — driven by margin compression from generic competition to core HIV products or increased R&D spend without corresponding revenue growth as shown in future EDGAR filings — would materially weaken the current bull case.
- If free cash flow coverage of the dividend declines in future 10-K data, pushing the FCF payout ratio into a less sustainable range, the dividend sub-score would fall and the company's best-fit profile score for dividend income would erode, reducing its primary research appeal.
Red Flags
- The financial health sub-score of 14.0/20 suggests the leverage ratio and/or interest coverage metrics as filed are meaningfully below optimal, warranting closer scrutiny of Gilead's debt load relative to its EBITDA and free cash flow generation.
- A theme score of 0.0/20 means the model found no macro theme alignment in the filing, which may indicate Gilead's core business areas — while commercially proven — are not positioned in the highest-priority emerging research or policy tailwind categories.
Risk Profile
Medium RiskThe Medium risk rating for Gilead reflects a company with strong profitability and an established dividend track record, balanced against a leveraged balance sheet (as evidenced by the 14.0/20 financial health sub-score) and revenue concentration in the HIV therapeutic area, both of which introduce meaningful downside scenarios. It is neither a distressed or speculative situation nor a low-leverage defensive, placing it in a middle tier where filing-based fundamentals are solid but structural vulnerabilities are present.
Key Catalysts to Watch
The key factors to watch in future EDGAR filings include the trajectory of Gilead's debt reduction and interest coverage improvement, which would directly affect the financial health sub-score, and any pipeline-driven revenue diversification into areas that the scoring model can recognize as macro theme exposure. Progress in the oncology cell therapy segment and any inflection in DPS growth CAGR would also be meaningful data points for the dividend income research profile.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.